Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Similar documents
Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

List of Designated High-Cost Drugs

29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?

National Cancer Drugs Fund List - Approved

Prior Authorization Approval Guidelines. May, 2017

Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee Implementation

NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust

April May For adults for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion.

New Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

Specialty Pipeline Update

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

ORAL ONCOLOGY CRITERIA

Specialty Pipeline Update

Specialty Pipeline Update

NB Drug Plans Formulary Update

Biologics for Autoimmune Diseases

Vectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:

NBPDP Formulary Update

Quarterly Report on Completed Drug Submission Reviews

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

Special Authorization

ORAL ONCOLOGY CRITERIA

Specialty Pipeline Update

2014 Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee

Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards

ACTEMRA (tocilizumab)

Prescription benefit updates Large group

OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT. Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

PA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*

Cosentyx. Cosentyx (secukinumab) Description

NICE TA Adherence Check list April Drug Indication NICE Approval Release Date

Medicine Condition being treated NHSGGC Decision Date of decision. 18 June 2018 Page 1 of 5

Criteria for Medical Benefit Drugs Requiring Clinical Review

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

Criteria for Medical Benefit Drugs Requiring Clinical Review

Pfizer Pipeline. November 8, 2012

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan

Cancer Therapy Update in 2017

04 September 2017 Page 1 of 6

April 2015 May SMC RECOMMENDED MEDICINES FOR USE Recommended for use within NHS Scotland April 2015 May 2015 Date SMC SMC Drug Name

Target date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished

2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018

Immune Modulating Drugs Prior Authorization Request Form

CIMZIA (certolizumab pegol)

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting

Medicare Part C Medical Coverage Policy

ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year

Pharmacy Medical Necessity Guidelines: Oral Cancer Medications

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

Provider Newsletter. Table of Contents. Reimbursement Policy: Improve member medication regimen. Page 2

NICE TA Adherence Check List

Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary

2018 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA

Pfizer Pipeline. August 9, 2012

Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division)

NB Drug Plans Formulary Update

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

Aetna Better Health. Specialty Drug Program

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Disclosure. Outline New Info on

Drug Name Generic Name J-Code Unclassified Drugs in excess of $10,000

Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

P&T/Formulary Committee Actions (1Q18)

March 2017 Pharmacy & Therapeutics Committee Decisions

Keytruda. Keytruda (pembrolizumab) Description

Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Pfizer Pipeline. May 10, 2012

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

NB Drug Plans Formulary Update

NICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017

Cimzia. Cimzia (certolizumab pegol) Description

Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017

Keytruda. Keytruda (pembrolizumab) Description

Actemra. Actemra (tocilizumab) Description

Canada s Rare Disease Strategy: Pathway to Timely Sustainable Access. CADTH Conference

PA Category Name Code(s) Additional Notes ABA. Applied Behavioral Analysis stage 3*

2019 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA

ELEVATE. Formulary Updates to Elevate Plans (Bronze HDHP/Standard, Silver Select/Standard & Gold Select/Standard)

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

Η συμβολή της φαρμακευτικής περίθαλψης στο επίπεδο υγείας. Prof. Nikos Maniadakis

Performance in delivering Clinical Research at PHT Q3 14/15 study met the 70 day target study within 70 day target study not met 70 day target

Transcription:

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of December 31, 2018 262 joint negotiations have been completed** for the following drugs and indications: Drug Product Brand Name (Generic Name) Abilify Maintena (aripiprazole long acting injection) Abraxane (nab-paclitaxel) Actemra (tocilizumab)* Actemra (tocilizumab) SC Actikerall (fluorouracil and salicylic acid) Adcetris (brentuximab) Adempas (riociguat) Advair (salmeterol xinafoate/fluticasone propionate) Afinitor (everolimus) Afinitor (everolimus) Alecensaro (alectinib)* Alecensaro (alectinib)* Alimta (pemetrexed) Anoro Ellipta (umeclidinium bromide/vilanterol trifenatate) Aptiom (eslicarbazepine) Arnuity Ellipta (fluticasone furoate) Aubagio (teriflunomide) Avastin (bevacizumab) Avastin (bevacizumab) Avastin (bevacizumab) Basaglar (insulin glargine) Blincyto (blinatumomab) Bosulif (bosutinib) Botox (onabotulinumtoxin A) Brenzys (etanercept) Breo Ellipta (fluticasone furoate/vilanterol) Breo Ellipta (fluticasone furoate/vilanterol) Brilinta (ticagrelor) Brivlera (brivaracetam) Cimzia (certolizumab) Caprelsa (vandetanib) Cosentyx (secukinumab) Indication/Use Please refer to individual jurisdictions for specific reimbursement criteria Used for the maintenance treatment of schizophrenia Used first-line to treat locally advanced unresectable or metastatic adenocarcinoma of the pancreas Used to treat giant cell arteritis Used to treat hyperkeratotic actinic keratosis Used to treat lymphoma Used to treat chronic thromboembolic pulmonary hypertension and asthma Used to treat pancreatic neuroendocrine tumours, and to treat breast cancer Used to treat neuroendocrine tumours of gastrointestinal or lung origin Used first line to treat locally advanced or metastatic non-small cell lung cancer Used second line to treat locally advanced or metastatic non-small cell lung cancer Used to treat lung cancer (new indication) Used to treat seizures Used to treat asthma Used to treat persistent, recurrent, or metastatic cervical cancer Used to treat epithelial ovarian cancer Used to treat genitourinary platinum-resistant ovarian cancer Used to treat metastatic colorectal cancer Used to treat type 1 and 2 diabetes mellitus Used to treat acute lymphoblastic leukemia Used to treat chronic myelogenous leukemia (CML) Used to treat multiple indications and ankylosing spondylitis Used for the treatment of asthma Used with ASA to prevent atherothrombotic events in patients with acute coronary syndrome Used to treat partial-onset seizures Used to treat ankylosing spondylitis, psoriatic arthritis Used to treat medullary thyroid cancer Used to treat moderate to severe plaque psoriasis

Cosentyx (secukinumab) Cosentyx (secukinumab) Cotellic (cobimetinib) Cyramza (ramucirumab) Daklinza (daclatasvir) Darzalex (daratumumab) Diacomit (stiripentol) Dificid (fidaxomicin) Duaklir Genuair (aclidinium bromide/formoterol fumarate dehydrate) Dysport Therapeutic (abobotulinumtoxin A) Dysport Therapeutic (abobotulinumtoxin A) Used to treat psoriatic arthritis Used to treat ankylosing spondylitis Used to treat gastrointestinal metastatic gastric cancer or gastroesophageal junction adenocarcinoma Used to treat chronic Hepatitis C infection Used to treat multiple myeloma Used in patients with severe myoclonic epilepsy in infancy Used to treat Clostridium difficile (COPD) Used to treat cervical dystonia Used to treat upper limb spasticity Dysport Therapeutic (abobotulinumtoxin A) Used for the symptomatic treatment of lower limb spasticity in pediatric patients Effient (prasugrel) Used with ASA to prevent atherothrombotic events in patients with acute coronary syndrome Elelyso (taliglucerase alfa) Used to treat Gaucher Disease Type 1 Eliquis (apixaban) Eliquis (apixaban) Enstilar (calcipotriol/betamethasone) Entresto (sacubitril/valsartan) Entyvio (vedolizumab) Entyvio (vedolizumab) Epclusa (sofosbuvir/velpatasvir) Erelzi (etanercept) Erivedge (vismodegib) Esbriet (pirfenidone) Esbriet (pirfenidone) Eylea (aflibercept) Eylea (aflibercept) Fabrazyme (agalsidase beta) Fabrazyme (agalsidase beta) Ferriprox (deferiprone) Fibristal (ulipristal acetate) Firazyr (icatibant) Forxiga (dapagliflozin) Galafold (migalastat) Galexos (simeprevir) Gazyva (obinutuzumab) Gazyva (obinutuzumab) Genvoya (elvitegravir/cobicistat/ emtricitabine/tenofovir alafenamide) Used to prevent strokes in patients with atrial fibrillation, and to prevent deep vein thrombosis Used to treat venous thromboembolic events and prevent recurrent deep-vein thrombosis and pulmonary embolism Used to treat psoriasis Used to treat heart failure Used to treat ulcerative colitis Used to treat Crohn s disease Used to treat ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis Used to treat metastatic basal cell carcinoma Used to treat idiopathic pulmonary fibrosis Used to treat idiopathic pulmonary fibrosis Used to treat neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and/or macular edema secondary to central retinal vein occlusion (CRVO) Used to treat macular edema secondary to branch retinal vein occlusion Used to treat Fabry disease Used to treat Fabry disease Used to treat Transfusional Iron Overload Used to treat uterine fibroids Used to treat acute attacks of hereditary angioedema Used to treat Type 2 diabetes Used to treat Fabry Disease Used to treat chronic hepatitis C Genotype 1 infection Used to treat chronic lymphocytic leukemia Used to treat follicular lymphoma Used to treat HIV-1 Infection

Gilenya (fingolimod) Giotrif (afatinib) Giotrif (afatinib) Glatect (glatiramer acetate) Grastofil (filgrastim) Halaven (eribulin) Harvoni (sofosbuvir/ledipsavir) Harvoni (sofosbuvir/ledipsavir) Hemangiol (propranolol) Holkira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir) Humira (adalimumab) Humira (adalimumab) Ibavyr (ribavirin) Ibrance (palbociclib) Iclusig (ponatinib) Ilaris (canakinumab) Imbruvica (ibrutinib) Imbruvica (ibrutinib) Imbruvica (ibrutinib) Incruse Ellipta (umeclidinium) Inflectra (infliximab) Inflectra (infliximab) Inlyta (axitinib) Inspiolto Respimat (tiotropium/olodaterol) Inspra (eplerenone) Invega Trinza (paliperidone palmitate) Invokana (canagliflozin) Istodax (romidepsin) Izba (travoprost)* Jadenu (deferasirox) Jakavi (ruxolitinib) Jakavi (ruxolitinib) Janumet (sitagliptin/metformin) Januvia (sitagliptin) Jardiance (empagliflozin) Jardiance (empagliflozin) Jetrea (ocriplasmin) Jevtana (cabazitaxel) Kadcyla (trastuzumab emtansine) Used to treat advanced non-small cell lung cancer Used to treat advanced non-small cell lung cancer Used for prevention or treatment of neutropenia in various indications Used to treat breast cancer Used to treat infantile hemangioma Used to treat ulcerative colitis Used to treat hidradenitis suppurativa Used to treat advanced breast cancer Used to treat Chronic Myeloid Leukemia (CML)/ Acute Lymphoblastic Leukemia Used to treat systemic juvenile idiopathic arthritis Used to treat chronic lymphocytic leukemia or small lymphocytic leukemia Used to treat relapsed/refractory Mantle Cell Lymphoma Used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma (COPD), ankylosing spondylitis, psoriatic arthritis, plaque psoriasis Used to treat ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn s disease and Ulcerative Colitis Used to treat metastatic renal cell carcinoma (COPD) Used to treat New York Heart Association (NYHA) class II systolic heart failure Used to treat schizophrenia Used to treat Type 2 diabetes Used to treat relapsed/refractory peripheral T-cell lymphoma Used to treat open-angle glaucoma Used to treat chronic iron overload Used to treat intermediate to high risk myelofibrosis Used to treat polycythemia vera Used to treat diabetes mellitus (Type 2) for patients with high cardiovascular risk Used to treat symptomatic vitreomacular adhesion Used to treat castration resistant metastatic prostate cancer Used to treat HER-2 positive metastatic breast cancer

Kalydeco (ivacaftor) Used to treat cystic fibrosis Keytruda (pembrolizumab) Keytruda (pembrolizumab) Used to treat non-small cell lung cancer (second line or beyond) Keytruda (pembrolizumab) Used to treat non-small cell lung cancer (first line) Kuvan (saproterin) Used to treat phenylketonuria Kyleena (levonorgestrel) Used for the prevention of pregnancy Kyprolis (carfilzomib) Used to treat multiple myeloma Kyprolis (carfilzomib) Used to treat multiple myeloma (relapsed) Lancora (ivabradine) Used to treat NYHA class II or III heart failure Lemtrada (alemtuzumab) Lenvima (lenvatinib) Used to treat thyroid cancer Lodalis (colesevelam) Used to treat hypercholesterolemia Lynparza (olaparib) Used to treat ovarian cancer Maviret (glecaprevir/pibrentasvir)* Used to treat hepatitis C MDK-Nitisinone (nitisinone) Used to treat hereditary tyrosinemia, type 1 Mekinist (trametinib) Metadol-D (methadone hydrochloride) Used to treat opioid dependence Metoject (methotrexate) Mictoryl (propiverine) Used to treat overactive bladder (paediatric) Mifegymiso (mifepristone/misoprostol) Used for the medical termination of pregnancy Mozobil (plerixafor) Used in combination with granulocyte colony-stimulating factor to support treatment for non-hodgkin lymphoma and multiple myeloma Mozobil (plerixafor) Used in combination with granulocyte colony-stimulating factor to support treatment for non-hodgkin lymphoma and multiple myeloma Myrbetriq (mirabegron) Used to treat overactive bladder Narcan (naloxone hydrochloride) Used to treat opioid overdose Neupro (rotigotine) Used to treat Parkinson's disease Nitisinone (nitisinone) Used to treat hereditary tyrosinemia, type 1 Nucala (mepolizumab) Used to treat severe eosinophilic asthma Ocaliva (obeticholic acid) Used to treat primary biliary cholangitis Odefsey (emtricitabine/rilpivirine/tenofovir Used to treat HIV-1 infection alafenamide) Ofev (nintedanib) Used to treat idiopathic pulmonary fibrosis Onbrez (indacaterol) Used as a bronchodilator for chronic obstructive pulmonary disease Onglyza (saxagliptan) Opdivo (nivolumab) Used to treat advanced or metastatic non-small cell lung cancer Opdivo (nivolumab) Opdivo (nivolumab) Used to treat advanced or metastatic renal cell carcinoma Opdivo (nivolumab) Used to treat squamous cell carcinoma of the head and neck (SCCHN) Oralair (grass pollen allergen extract) Used to treat allergic rhinitis with or without conjunctivitis Orencia (abatacept) Orfadin (nitisinone) Used to treat hereditary tyrosinemia, type 1 Perjeta (pertuzumab) Used to treat breast cancer Pheburane (sodium phenylbutyrate) Used to treat urea cycle disorders Plegridy (PegIFN beta-1a) (RRMS)

Pomalyst (pomalidomide) Pomalyst (pomalidomide) Second letter of intent Praluent (alirocumab) Pradaxa (dabigatran) Prezcobix (darunavir/cobicistat) Procysbi (cysteamine bitartrate) Prolia (denosumab) Quinsair (levofloxacin) Ravicti (glycerol phenylbutyrate) Rebif (interferon beta-1a) Remicade (infliximab) Renflexis (infliximab) Repatha (evolocumab) Replagal (agalsidase alfa) Replagal (agalsidase alfa) Revestive (teduglutide) Revlimid (lenalidomide) Revlimid (lenalidomide) Rexulti (brexpiprazole)* Rituxan SC (rituximab) Rituxan SC (rituximab) Rydapt (midostaurin) Seebri Breezhaler (glycopyrronium bromide) Siliq (brodalumab)* Simbrinza (brinzolamide/brimonidine) Simponi (golimumab) SC Soliris (eculizumab) Sovaldi (sofosbuvir) Sovaldi (sofosbuvir) Spinraza (nusinersen) Spiriva Respimat (tiotropium) Stivarga (regorafenib) Stivarga (regorafenib) Strensiq (asfotase alfa) Stribild (elvitegravir/cobicistat/ emtricitabine/tenofovir) Sunvepra (asunaprevir) Sutent (sunitinib) Used to treat multiple myeloma Used to treat multiple myeloma Used for lowering of low density lipoprotein cholesterol (LDL-C) in patients with heterozygous familial hypercholesterolemia (HeFH) Used to prevent strokes in patients with atrial fibrillation Used to treat HIV-1 infection Used to treat nephropathic cystinosis Used to treat osteoporosis Used to treat cystic fibrosis with chronic Pseudomonas aeruginosa infections Used to treat urea cycle disorders Used for clinically isolated syndrome Used to treat multiple indications including rheumatoid arthritis, ulcerative colitis and Crohn s disease, ankylosing spondylitis, adult Crohn s disease, pediatric Crohn s disease, fistulising Crohn s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis Used to treat primary hyperlipidemia and mixed dyslipidemia Used to treat Fabry Disease Used to treat Fabry Disease Used to treat short bowel syndrome (SBS) Used for maintenance treatment in multiple myeloma after a stem cell transplant Used to treat newly diagnosed multiple myeloma Used to treat schizophrenia Used to treat multiple indications Used to treat chronic lymphocytic leukemia Used to treat Acute Myeloid Leukemia Used to treat moderate to severe plaque psoriasis Used to treat glaucoma and ocular hypertension Used to treat ulcerative colitis Used to treat paroxysmal nocturnal hemoglobinuria Used to treat 5q Spinal Muscular Atrophy Used to treat metastatic and/or unresectable gastrointestinal stromal tumours (GIST) Used to treat metastatic and/or unresectable gastrointestinal stromal tumours (GIST) Used to treat pediatric-onset hypophosphatasia Used to treat HIV-1 infection in antiretroviral treatment-naïve adult patients Used to treat chronic Hepatitis C Used to treat pancreatic neuroendocrine tumours

Synjardy (empagliflozin and metformin) Sylvant (siltuximab) Tafinlar (dabrafenib) Tafinlar (dabrafenib) and Mekinist (tramatinib) Tagrisso (osimertinib) Taltz (Ixekizumab) Taltz (ixekizumab)* Tecentriq (atezolizumab)* Tecfidera (dimethyl fumarate) Tivicay (dolutegravir) Tobi Podhaler (tobramycin) Tradjenta (linagliptin) and Jentadueto (linagliptin/metformin) Treanda (bendamustine) Toujeo (insulin glargine) Tresiba (insulin degludec) Triumeq (dolutegravir/abacavir/lamivudine) Tudorza Genuair (aclidinium bromide) Tysabri (natalizumab) Ultibro (indacaterol/glycopyrronium) Uptravi (selexipag) Valtrex (valacyclovir) Vectibix (panitumumab) Vimizim (elosulfase alfa) Vosevi (sofosbuvir velpatasvir voxilaprevir) Votrient (pazopanib) Used to treat type 2 diabetes mellitus in patients with high cardiovascular risk Used to treat multicentric Castleman s disease (in combination) Used to treat locally advanced or metastatic EGFR T790M mutationpositive non-small cell lung cancer (NSCLC) who have progressed on or after EGFR TKI therapy Used to treat moderate to severe plaque psoriasis Used to treat psoriatic arthritis Used to treat non-small cell lung cancer Used to treat multiple sclerosis Used to treat HIV-1 infection Used for the management of cystic fibrosis patients with chronic pulmonary Pseuodomonas aeruginosa infections Used to treat non-hodgkin lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia Used to treat type 1 and type 2 diabetes mellitus Used to treat type 1 and type 2 diabetes mellitus Used to treat HIV-1 infection Used in management of chronic obstructive pulmonary disease (COPD) Used to treat pulmonary arterial hypertension Used to treat specific viral infections Used to treat metastatic colorectal cancer Used to treat mucopolysaccharidosis IVA (Morquio A syndrome) Used to treat metastatic renal cell carcinoma Votrient (pazopanib) Used to treat metastatic renal cell carcinoma VPRIV (velaglucerase) Used to treat Gaucher Disease Type 1 Xalkori (crizotinib) Xalkori (crizotinib) Xarelto (rivaroxaban) Xarelto (rivaroxaban) Xeljanz (tofacitinib) XigDuo (dapagliflozin/metformin hydrochloride) Xolair (omalizumab) Xtandi (enzalutamide) Xtandi (enzulatamide) Yervoy (ipilimumab) Used to treat advanced non-small cell lung cancer (second-line) Used to treat advanced non-small cell lung cancer (first-line) New indication for treatment of venous thromboembolic events and prevention of recurrent deep vein thrombosis and pulmonary embolism. Used to prevent strokes in patients with atrial fibrillation, and to prevent deep vein thrombosis Used to treat type 2 diabetes mellitus Used to treat chronic idiopathic urticaria Used to treat first-line metastatic castrate resistant prostate cancer (before chemotherapy) Used to treat castrate resistant prostate cancer (after chemotherapy) Used for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma

Yervoy (ipilimumab) Used for the second-line treatment of adult patients with unresectable or metastatic melanoma Zaxine (rifaximin) Used to treat hepatic encephalopathy Zepatier (elbasvir grazoprevir) Used for the treatment of Hepatitis C (genotype 1, 4) Zydelig (idelalisib) Used to treat relapsed chronic lymphocytic leukemia (CLL) Zykadia (ceritinib) Used to treat ALK+ non-small cell lung cancer Zytiga (abiraterone) Used to treat prostate cancer 30 drug negotiations were closed as agreements were not reached: Abilify (aripiprazole) Used for the treatment of schizophrenia and related psychotic disorders Adempas (riociguat) Used to treat pulmonary arterial hypertension Brilinta (ticagrelor) Used with ASA to prevent atherothrombotic events with history of myocardial infarction Butrans (buprenorphine) Used to treat persistent pain of moderate intensity Byetta (exenatide) Used to treat Type 2 diabetes Campral (acamprosate calcium) Used for maintenance of alcohol abstinence Caprelsa (vandetanib) Used to treat medullary thyroid cancer Cerdelga (eliglustat) Used to treat Gaucher Disease Type 1 Cerezyme (imiglucerase) Used to treat Gaucher Disease Type 1 Cinqair (reslizumab) Used to treat severe eosinophilic asthma Copaxone (glatiramer acetate) Used to treat multiple sclerosis Daklinza (daclatasvir) Used to treat chronic Hepatitis C Descovy (emtricitabine/tenofovir Used to treat HIV-1 infection alafenamide) Fibristal (ulipristal acetate) Used to treat uterine fibroids (2nd cycle pre-surgery) Invokamet (canagliflozin/metformin Used to treat type 2 diabetes mellitus hydrochloride) Kalydeco (ivacaftor) Used to treat cystic fibrosis with G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, G970R or R117H mutation Kevzara (sarilumab) Methadose (methadone) Used to treat opioid dependence Mictoryl (propiverine) Used to treat overactive bladder Opsumit (macitentan) Used to treat pulmonary arterial hypertension Otezla (apremilast) Used to treat moderate to severe plaque psoriasis Otezla (apremilast) Used to treat psoriatic arthritis Rosiver (ivermectin) Used to treat rosacea Rosiver (ivermectin) Used to treat rosacea Simponi (golimumab) IV Soliris (eculizumab) Used to treat ahus Strensiq (asfotase alfa) Used to treat hypophosphatasia Technivie (ombitasvir/paritaprevir/ Used for the treatment of Hepatitis C (genotype 4) ritonavir) Vemlidy (tenofovir alafenamide) Used to treat chronic hepatitis B infection Victoza (liraglutide) Used to treat Type 2 diabetes

** A completed pan-canadian negotiation refers to those for which a Letter of Intent (document which outlines the agreed upon terms and conditions for listing) has been signed between the lead jurisdiction for the negotiation and the manufacturer OR negotiations have been closed without a Letter of Intent. The initial nine products negotiated through the pcpa. * New negotiations that have been completed since last update on November 30, 2018